We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Kedem Pharmaceuticals Introduces Their Sublingual Drug Delivery System

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Kedem Pharmaceuticals Introduces Their Sublingual Drug Delivery System"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The company CEO Dr. Hasssan Salari will be on hand to discuss with the attendees the company's progress on X-Excite, the Company's lead therapeutic drug for erectile dysfunction. The Company's second lead therapeutic drug KDM-1102, which is a new sublingual formulation of Propanolol for cardiovascular diseases. The newest drug initiated into development of Gleevec(R). Gleevec(R) is an important anti-cancer drug for the treatment of several blood related cancers in children and adults.

Dr. Hassan Salari, Ph.D, C.E.O. expressed, "We were pleased to Welcome the Investors at the World Money Show forum and are excited to have a platform for review by the investment community. We welcome the opportunity to inform our shareholders in more detail about our goals to commercialize our sublingual drug delivery system.

If you are not attending the show you can visit our virtual E-Booth by registering at the link https://secure.moneyshow.com/Virtual_Show_Reg/TWMS/registration.asp?sid=TWMS12&scode=013104